2022 in review

STALLERGENES GREER

Life beyond allergy

"By building on existing momentum, focusing on high quality operations and investing for the long-term, we will continue to deliver innovative treatments for patients across the globe while creating sustainable value for the Group's stakeholders."

Message from our Chairman

Stefan Meister *Chairman of the Board of Directors*

The past year, marked by an unstable geopolitical situation, resurgent inflation, and the continued economic impact of the pandemic, brought its many challenges. Despite these conditions, Stallergenes Greer posted solid performance in 2022 and stayed true to its mission of delivering high-quality treatments to improve the quality of life of patients with allergies.

Throughout the year, Stallergenes Greer continued to rigorously execute on its strategy, strengthen its financial profile, and boost its operational resiliency while gaining market share in many territories. The Group also made progress on its move towards a leaner organisation, while increasing its focus on innovation and corporate responsibility.

As the pace of change continues to accelerate, Stallergenes Greer's robust fundamentals combined with the support of its sole shareholder, B-FLEXION, are unique assets for the future. They further enhance the Group's ability to explore new frontiers in allergen immunotherapy and discover and develop novel treatments for patients.

Stallergenes Greer's people play a key role in the Group's success. On behalf of the Board of Directors, I would like to take this opportunity to recognise their engagement and contribution to the Group's achievements throughout the year, and to thank Michele Antonelli for his continued executive leadership of all our people.

Stallergenes Greer has set out a clear path towards fulfilling its ambition of becoming the world's leading allergen immunotherapy company. By building on existing momentum, focusing on high quality operations and investing for the long-term, we will continue to deliver innovative treatments for patients across the globe while creating sustainable value for the Group's stakeholders.

Sincerely,

Stefan Meister

Interview with our CEO

Michele Antonelli *Chief Executive Officer*

How would you summarise 2022 and what were Stallergenes Greer's greatest challenges and achievements?

2022 was a challenging year both for our industry and for society as a whole. Among the challenges we had to face the most significant were patients slowly returning to see their allergist in the wake of the pandemic, and, with physicians being called back to hospitals, a decreased availability in private practices. Furthermore, waiting lists to consult specialist doctors are long which may discourage some patients. And, in allergology we are also witnessing an imbalance between the number of physicians retiring and new ones joining the field. At the same time, the number of people with allergies in need of treatment is increasing steadily.

The current geopolitical situation, which has given rise to global uncertainty and increasing energy prices, but also to logistical issues and supply shortages, was, and continues to be, a source of concern for us all.

The breakdown of the ecosystem of work, home and well-being has also given rise to other challenges. With people becoming more mobile, looking for new roles, higher compensation and benefits, and more flexible work schedules, we are all competing for talent. As a company, we must continue to make every effort to remain attractive, ethical, patient-focused, and a responsible corporate citizen.

Despite these challenges, we pursued our efforts with determination and delivered double-digit growth in 2022, in line with our objectives. We launched our house dust mite allergy tablet in nine European countries and initiated several strategic projects which will contribute to our future growth. We are also reaping the benefits, in terms of quality, security and efficiency, of sustained investments in our industrial assets.

What are the key factors which fuelled this growth?

Several factors contributed to our performance in 2022: our people, the successful ongoing transformation of our organisation, product quality and security, and our ability to innovate.

In 2022, we intensified our efforts regarding the development of our people. To ensure our employees are geared to tackle present and future challenges, we focused training on talent development and performance, and the strengthening of management and leadership skills. We are also embedding a lean culture throughout the Group with Six Sigma training. Over the past years, Stallergenes Greer has moved from a traditional organisation to one that is project based. Our lean and agile mindset contributes to creating value for our stakeholders.

The quality of our products and our drive to innovate are key factors of our performance. We continually invest in technologies, equipment, and skills to increase quality and compliance. Product quality is an ongoing journey, a journey in which each employee is fully engaged. Our ability to innovate and partner with the right organisations will also support us in facing future challenges. With iPUMP for instance, our connected system for SLIT treatment developed with a partner, we are taking drug delivery modes one step further for the benefit of patients.

What are the benefits of precision medicine for patients, physicians and healthcare systems?

I believe that our advancements in precision medicine are one of the main results of this year. At Stallergenes Greer, we are continuously asking ourselves how we can provide a patient with the treatment which is best adapted to his or her condition, needs and profile.

We offer products that are supported by a wealth of data documenting their effectiveness. Our five real-world evidence studies, which analyse data from more than 100,000 exposed patients, are a true asset. They help us examine subsets of patients on a larger scale and guide us toward more precise treatment options from a genetic point of view. Whether we are researching new molecular entities, food allergies or novel delivery modes, we seek therapeutic solutions which are tailored to each individual. By leveraging the full potential of precision medicine, we aim to provide better care and value, and maximise the treatment outcome for each patient while reducing overall costs for healthcare systems.

2022 also marked the redefinition of Stallergenes Greer's corporate responsibility programme. Can you tell us more?

As a good corporate citizen, we have a duty to act responsibly, to innovate for patients and society, to foster a safe, diverse, dynamic and inclusive workplace, and to do our part to protect natural resources.

Over the past months, we formalised our corporate responsibility priorities in a programme called *Care Beyond Allergy*. Our approach to corporate responsibility aims to better serve patients, physicians, colleagues, and partners, while enhancing our success as a business. *Care Beyond Allergy* encompasses four key pillars which emphasise our responsibility and focuses on areas in which we can make a difference: society, environment, social and governance.

We are at the beginning of our journey and each one of us has a part to play in making a positive contribution to society as a whole and to the planet.

What makes you optimistic when you look to the future?

There remains much uncertainty in the world, however, our performance is the demonstration that we can succeed by remaining committed to our purpose of enabling precision medicine to improve life for people with allergies and continuing to make confident decisions.

I am optimistic about the future because I know we have the right people to stay the course and deliver on our long-term strategy. We have the know-how, skills, and the commitment to discover and develop novel technologies. We are making strides in advancing precision medicine for the benefit of people with allergies.

The support of our shareholder, combined with our solid financials, provide us with the means to accelerate our growth and achieve our ambition.

Our efforts are recognised by patients and healthcare professionals who benefit from our allergen immunotherapy solutions and our commitment to discover and develop novel treatments in the field of allergies.

"By leveraging the full potential of precision medicine, we aim to provide better care and value, and maximise the treatment outcome for each patient while reducing overall costs for healthcare systems."

About Stallergenes Greer

At a glance

Stallergenes Greer is a fully integrated global biopharmaceutical company specialising in the research, diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy (AIT) products and services.

The Group's extensive product portfolio, available in multiple formulations (subcutaneous, sublingual drops and tablets), offers patients innovative solutions to improve quality of life for people with allergies.

A world leader in allergen immunotherapy, Stallergenes Greer has an extensive global footprint and the largest allergen and finished AIT product manufacturing capacity globally.

19
countries with a direct presence

41
countries with a distribution network

1,102
employees worldwide

San Diego, California, U.S.
Production of bulk allergens and custom-order products

Mathiston, Mississippi, U.S.
Production of source materials (pollen)

Dutton, Ontario, Canada
Preparation of named patient subcutaneous immunotherapy

Lenoir, North Carolina, U.S.
Production and processing of source materials, bulk allergens and supplies for human and veterinary use

Antony, France
Production of sublingual (drops and tablets) and subcutaneous AIT products

Amilly, France
Production of source materials (pollen) and securing of house dust mite strains

Our purpose

Enabling precision medicine to improve life for people with allergies.

Our ambition

Becoming the world's leading allergen immunotherapy company.

Our strategy

Our strategy is designed to achieve our ambition of being the world's leading allergen immunotherapy company for the long-term and deliver sustainable value to all our stakeholders: patients, the medical community, healthcare systems, colleagues, and our shareholder.

To achieve our ambition, our strategy is based on four pillars: excellence in execution, strengthening our core business, developing new solutions for patients, and attracting and developing talents.

Excellence in execution

Our ambition is to serve patients with high-quality products and optimal solutions to treat allergies thanks to a robust supply chain and state-of-the-art pharmaceutical technologies.

Strengthening our core business

Expanding our geographical footprint to reach more patients in need of precise, personalised treatments. We aim to offer physicians the broadest portfolio of allergens and delivery systems to foster precision medicine and deliver successful patient outcomes.

Developing new solutions for our patients

For the benefit of patients across the globe, our objective is to further enrich the evidence of our treatments with new clinical and real-world data, improve treatment adherence with novel delivery tools, and discover and develop innovative products to treat respiratory and food allergies.

Attracting and developing our talents

Our people are our greatest asset. They design, develop, and deliver solutions which are tailored to the individual needs and profile of patients. We invest in the development of our colleagues who are committed to improving the quality of life of allergy sufferers.

Governance

Stallergenes Greer is governed by a Board of Directors which determines the strategic direction of the Group.

The Executive Committee, chaired by the Chief Executive Officer, is comprised of senior leaders who represent a breadth and depth of knowledge and experience to lead our business. Together, they form a forward-thinking, collaborative, multicultural group of leaders that drive our culture of success and support our growth worldwide.

Our shareholder

Stallergenes Greer is a private company owned by interests associated with the Bertarelli family, which are advised by the B-FLEXION group. B-FLEXION is a private, entrepreneurial investment firm, delivering exceptional value over the generations, while also contributing positively to society.

B-FLEXION continues to drive expansion by growing operating businesses in transformative industries. In keeping with – and building upon – its heritage, these are principally in the fields of life sciences, healthcare services and digital health.

Chaired by Ernesto Bertarelli, B-FLEXION has offices across Europe and in the United States.

Michele Antonelli

Chief Executive Officer

Michele Antonelli has been CEO of Stallergenes Greer since January 2019. He joined the company in 2015 as Head of Europe and International. Previously, Michele Antonelli held roles of increasing responsibility and scope at UCB, most recently serving as EVP and Head of Immunology Europe, overseeing the region's commercial, medical, and market access activities. Prior to UCB, Michele Antonelli spent 16 years at Merck Serono, ultimately serving as SVP and Global Head of Biotech Manufacturing and Process Development.
Michele Antonelli is Swiss and Italian.

Amer Jaber

Executive Vice President Operations, Europe and International

Amer Jaber joined Stallergenes Greer in 2018. Prior to joining Stallergenes Greer, Amer Jaber was Head of Biotechnology Operations at R-Pharm responsible for developing the long-term strategy and execution of technical operations for CMC Development and Manufacturing. Amer Jaber was previously Head of Global Biotech Development and Manufacturing for Technical Operations and Managing Director of UCB Switzerland. Before joining UCB, he held roles of increasing responsibility at Mondobiotech, Serono International and Rivopharm.
Amer Jaber is Lebanese and Swiss.

Dominique Pezziardi

General Manager France, Belgium and Luxembourg - Global Head of Pricing and Market Access

Dominique Pezziardi joined Stallergenes Greer in 2012 as Head of Strategy and Business Operations. Prior to joining Stallergenes Greer, Dominique Pezziardi gained his expertise in several therapeutic fields including fertility, growth hormones, diabetes, rare diseases, cardiology and medical devices in the pharmaceutical sector at Ciba, Sanofi and Merck Serono. He successfully managed global product launches, life cycle development plans, mature franchise relaunches, alliances with strategic partners, and more recently, corporate strategy development.
Dominique Pezziardi is French.

Tibor Nemes

Executive Vice President, Head of Americas

Tibor Nemes joined Stallergenes Greer in 2016 and served as Global Head of Technical Operations before taking over as Head of the Americas in May 2018. Tibor Nemes previously spent eight years at Novartis where he held roles of increasing responsibility, most recently as the Global Operations Head, Tech Ops Manufacturing, Strategy and BDM&A. Prior to Novartis, Tibor Nemes held Engineering and Operations leadership roles at Novavax, Inc., Bristol-Myers Squibb Company, Elan Pharmaceuticals and Hypex, Inc.
Tibor Nemes is American.

Valérie Benhamou

General Counsel

Valérie Benhamou joined Stallergenes Greer in 2017 as Associate General Counsel Europe and International. Valérie Benhamou joined the company from Abbott, where she was Senior Legal Counsel for France, Benelux and Africa. Prior to Abbott, she served as Senior counsel for Bristol-Myers Squibb where she provided legal support to all divisions in France and to EMEA commercial operations and practiced at law firms where she focused on healthcare matters. She has been a member of the Paris Bar since 1999.
Valérie Benhamou is French.

Nicola Lamacchia

Chief Financial Officer

Nicola Lamacchia joined Stallergenes Greer in 2017 as Head of Finance for the Europe and International region. Prior to joining Stallergenes Greer, he was Head of Finance for International at Shire, leading the creation of a new financial framework and supporting the company's growth and expansion. Prior to Shire, Nicola Lamacchia held several country, regional and division-level financial roles at Merck Serono.
Nicola Lamacchia is Swiss and Italian.

Jérôme Tilly

Senior Vice President, Human Resources

Jérôme Tilly joined Stallergenes Greer in 2014 as Senior Vice President Human Resources, Europe and International. Jérôme Tilly joined the company from Sogefi, an Italian automotive supplier, where he served as Vice President Human Resources. Throughout his career, Jérôme Tilly held positions of increasing responsibility and gained in-depth knowledge of human resources at automotive, airport ground handling and media companies.
Jérôme Tilly is French.

Petr Tor

Senior Vice President, Commercial Operations, Europe and International

Petr Tor joined Stallergenes Greer in 2010 as General Manager of the Czech and Slovak subsidiary and since 2014 he has held commercial responsibilities for various regions of increasing scope and complexity in Europe, the Middle East and Africa. Petr Tor gained his expertise in several therapeutic fields including asthma, cardiology, diabetes, glaucoma, antibiotics and HIV at Merck & Co., where he spent 16 years.
Petr Tor is Czech.

Environment

Market environment

Approximately 30% of the world population is affected by one or more allergic conditions[1], and it is expected that by 2050, several billion people will suffer from allergies[2].
The increasing prevalence and intensity of allergies is a trend that has continued in the industrialised world for more than 60 years.

Allergies impact quality of life and can trigger asthma

The limitations resulting from the body's reaction to allergens are multifaceted but share one common theme: the patient's quality of life is no longer the same. People who are sensitised to aeroallergens develop allergic rhinitis with symptoms such as a runny nose, itching, watery eyes, respiratory congestion, and fatigue. A less well-known and often underestimated consequence is that allergies put people at a greater risk of developing asthma.

People with allergic rhinitis are three times more likely to develop asthma than other people, and the risk for patients with house dust mite-induced allergic rhinitis is about six times higher than those whose allergic rhinitis is caused by grass pollen.

Too many patients are not treated

Allergic rhinitis affects approximately 10% to 30% of adults and 40% of children. Only approximately 12%[3] of people suffering from allergic rhinitis are treated with allergen immunotherapy (AIT) products due to low awareness among physicians and patients, a complex treatment pathway, and a market that is dominated by lower cost symptomatic treatments. AIT is the only treatment that addresses the underlying cause of allergy and may provide both rapid (within a few weeks) and long-lasting (several years) improvement of all symptoms, whereas symptomatic treatments (such as antihistamines and corticosteroids) only temporarily relieve some allergy symptoms.

With a modest proposal rate, the AIT market is underdeveloped,

representing approximately €1bn or 12% of the global allergic rhinitis market and is expected to grow by 2% p.a. in the coming years[3].

Market growth should result from increased awareness of respiratory allergies, easier access to allergists, the expanded range of administration modes as well as a growing middle class in developing countries that will gain access to medical treatment.

Innovation in science and technology is creating new medical opportunities

Biologics, gene therapies and other new molecularly targeted compositions are starting to deliver on their promise to enable more precise diagnostics and more tailored treatments. The development of patient-friendly treatments (shorter treatment lengths, ease of use) should improve AIT penetration in the allergic rhinitis patient population and their adherence.

In addition, advances in the areas of genetics and informatics are driving a transformation in our understanding of the disease. Innovations in technology also present opportunities to address the growing volume of regulatory requirements more efficiently and more effectively.

Rise in allergies gaining attention from payers, providers, and regulators

As more patients seek treatment for their allergies, the AIT industry is gaining greater attention from the healthcare community. Healthcare providers are seeking more clinical evidence related to the safety and efficacy of AIT; payers are tightly controlling access and increasingly requiring data about the economic benefit to maintain coverage for treatment; and regulatory bodies are intensifying their scrutiny of, and enacting more stringent requirements on, biologics manufacturers.

1. World Allergy Organization, Immunology and Biologics Symposium 2013. https://worldallergy.org/symposium2013 - 2. Lotvall, J., R. Pawankar, D. V. Wallace, C. A. Akdis, L. J. Rosenwasser, R. W. Weber, A. W. Burks, T. B. Casale, R. F. Lockey, N. G. Papadopoulos, S. M. Fineman and D. K. Ledford (2012). "We call for iCAALL: International Collaboration in Asthma, Allergy and Immunology." The Journal of allergy and clinical immunology 129(4): 904-905. - 3. Market size (€1bn) and expected growth (2%): global data and internal estimates share of AIT market in the global allergic rhinitis market (12%): Visiongain report 2018.

Environment

Allergens

Allergy is a disorder of the immune system which reacts to a normally harmless foreign substance such as house dust mites, pollens, or certain foods.

In people with allergies, the immune system produces antibodies that identify a particular allergen as harmful following contact, ingestion or even inhalation. The immune system's reaction can cause inflammation of the skin, sinuses, respiratory airways, or digestive system.

Allergies are a common, chronic, often debilitating condition that often affects the patient's quality of life and can sometimes even cause anaphylaxis, a fatal reaction.

Allergy diagnosis

The diagnosis of respiratory allergies is based on clinical history, physical examination, allergy tests and specific questions. One of the diagnostic methods used by medical practitioners to identify the triggering allergens in patients is a skin prick test.

Via a prick to the skin, the patient is exposed to the suspected allergen and is monitored. After approximately 20 minutes, the skin is observed for any signs of reaction to one or several of the allergens: redness, swelling, itching.

Allergen immunotherapy

Allergen immunotherapy (AIT) is an allergy treatment designed to treat the underlying cause of the disease as well as have a long-lasting effect on all symptoms. After an accurate diagnosis of the type of allergy and responsible allergens, patients, in line with their healthcare practitioner's prescription, receive a targeted treatment, available either in sublingual (tablets or solutions) or subcutaneous (injections) form depending on product availability in each country.

Because it treats the root cause, AIT results in immunologic tolerance, i.e., a decrease in the body's reaction to an allergen. Through the repeated administration of specific allergens to patients, the immune system builds resistance by changing the types and proportions of antibodies (immunoglobulins) and proteins (interleukins) it produces when it is exposed to the allergen, thus reducing symptoms when patients are exposed to the allergen in their environment – even after treatment ends. AIT usually requires 3 to 5 years of treatment[1].

1. Marogna M. et al., Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year study. J Allergy Clin Immunology, 2010)

Human allergies

Potential allergy symptoms in humans cover a variety of symptoms which can range from mild to severe. If left untreated allergy symptoms can worsen over time.

Symptoms vary from one person to another and according to the allergy and include: psychological symptoms (fatigue, irritability, poor sleep, negative effect on concentration and performance); allergic conjunctivitis with itchy, red and watery eyes; allergic rhinitis with sneezing and blocked or runny nose; swelling and itching in the oral area; suffocation by swelling of the throat and larynx; allergic asthma with dry cough and shortness of breath; skin or digestive discomfort; wheezing; constricted airways in the lungs; severe lowering of blood pressure and shock.

Veterinary allergies

Animals can suffer from many of the same ailments as people. Most allergies in animals fall into three categories: environmental allergies, food allergies, and insect-bite allergies.

Allergies in animals can have a significant impact on quality of life and can strain the relationships between people and their companion animal. Symptoms of potential allergies in companion animals such as dogs, cats and horses (symptoms vary according to species) include: itchiness (excessive scratching, licking, chewing themselves, overgrooming, rubbing against trees, fences, stalls or rolling in the dirt or grass); red, inflamed skin, small scabs or crusts on the body; fur loss; frequent, recurrent ear infections and/or anal gland problems; hives; digestive discomfort; sneezing and runny nose and/or eyes.

Grasses

Grasses are one of the most common causes of allergies. The pollen released by grass can be carried by the wind over many miles.

Trees

Tree pollen is the first seasonal allergy of the year, with some trees releasing pollen in January. Trees that trigger allergies include ash, beech, birch, cedar, elm, mulberry, olive, poplar, willow, etc.

Weeds

Weed pollen season occurs from spring to early autumn. Weeds that trigger allergies include mugwort, nettle, lamb's quarters, ragweed, sage, Russian thistle, etc.

Air pollutants

Traffic-related emissions are a significant source of air pollution and can worsen allergic rhinitis symptoms and asthma. Industrial air pollutants and particulates can exacerbate allergic rhinitis and asthma as well as modify the allergenic potential of certain pollens.



House dust mites

House dust mites belong to the Arachnida class, which includes spiders and ticks. They measure between 0.2-0.4 mm and are present in all households where they tend to be more numerous in bedding, upholstery, carpets, etc.



Food allergies

The most common food allergies are triggered by milk, egg, peanut, tree nut, soy, wheat, fish and shellfish. While most symptoms from food allergies are mild and limited to skin or digestive discomfort, some people may develop anaphylaxis which can lead to constricted airways in the lungs, severe lowering of blood pressure and shock and suffocation by swelling of the throat and larynx.

Insect venom

Insect venom stings can cause severe reactions in people with allergies. While some will have only minor reactions to stings, others may have a life-threatening allergic reaction and go into anaphylactic shock. Venoms responsible for allergic reactions include species from the Hymenoptera order including honey bees, hornets, wasps and yellowjackets.



Pets

Animals with fur can be a source of allergy. The body reacts to dead flakes of skin shed by animals. What triggers an allergic reaction isn't pet fur, but a substance found on the pet's fur; this allergen is produced by the skin of felines and is also present in their saliva, urine, tears and dander.



Latex

Natural rubber latex, the protein in the sap of the Brazilian rubber tree, is found in many consumer goods (balloons, rubber bands, etc.). Latex allergy symptoms may include hives, itching, stuffy or runny nose. It can cause asthma symptoms with difficulty breathing and can result in anaphylaxis.



Mould, mildew

Fungi can be found both indoors in damp areas (bathroom, kitchen, etc.) and outdoors (fallen leaves, compost, grasses, etc.). The spores produced by the fungi are released by wind and dew.

Environment

Patient journey

Respiratory allergies follow a chronic and progressing disease course, especially when left untreated[1]. Allergic rhinitis is often under-diagnosed and a patient may have waited six years after the onset of symptoms to see a specialist[2].

Patients may have waited

6

years after the onset of symptoms to see a specialist[1]

Globally, over

400

million people[3] suffer from allergic rhinitis

Asthma and allergic rhinitis are estimated to result in more than

100

million[4] lost workdays and missed school days every year

Allergen immunotherapy is used in less than

10%[5]

of eligible patients

1. Bousquet J, et al. Allergy 2008;63(S86):8–160. 2. Canonica GW, et al. World Allergy Organization Journal (2015) 8:10 DOI 10.1186/1939-4551-8-10 3. Pawankar, R. (2014). Allergic diseases and asthma: a global public health concern and a call to action. BioMed Central. 4. European Academy of Allergy and Clinical Immunology Advocacy Manifest o: https://emj.emg-health.com/wp-content/uploads/sites/ Connecting-the-Dots-Between-S Jutel M, et al. Allergy 2015;70:115–120 5. Jutel M, et al. Allergy 2015;136:556–68

What we do

Precision medicine

We believe patients deserve an allergen immunotherapy solution which is tailored to their needs and profile. We are determined to fully leverage the potential of precision medicine for the benefit of people with allergies.

Pushing the boundaries of science to leverage the potential of precision medicine

Precision medicine consists in using the individual characteristics and mechanism of disease of each patient to evaluate the efficacy and safety of our AIT treatments, while reducing costs both for patients and healthcare authorities.

At Stallergenes Greer, one of the ways we are doing this is by characterising the molecular immunological responses of each patient and exploring molecular diagnostics to identify, with increased precision, the allergens to which each patient is specifically sensitive.

The development of new disciplines and skills are making it possible to specify the diagnosis of respiratory allergy for each individual. Molecular diagnostics provide additional information to guide the prescription and composition of allergen immunotherapy treatments.

Precise personalised allergen immunotherapy solutions

Because each patient presents a unique immunologic profile, we believe that one solution doesn't fit all. Stallergenes Greer's approach allows healthcare professionals to create, along with first-line treatments such as allergen eviction and symptomatic medication, a tailored approach that best addresses each individual's treatments needs.

Science

Precision medicine is the focus of Stallergenes Greer's strategy.
We develop precise and personalised therapeutic solutions tailored to the individual profile and needs of each patient.

A high level of scientific expertise

We focus our efforts on allergen characterisation and on optimal approaches to deliver allergens to the immune system. Each allergen source contains several molecules which are recognised by the immune system as allergens and will trigger an allergic reaction.

Allergens are large, complex molecules. Working with large molecules requires a high level of scientific expertise and state-of-the-art technologies to characterise and quantify allergens. Specific processes are required due to both the complexity of the molecules and their biological nature.

Focusing on precision medicine to advance personalised solutions

Stallergenes Greer boasts a long-standing expertise regarding the mechanism of action of AIT and has been intensifying the identification of biomarker candidates to predict and monitor the efficacy of the Group's AIT treatments. We continue to work towards identifying the most relevant allergens for the treatment of allergies and partner with renowned academics in the field of respiratory allergies to characterise the molecular profiles of allergic patients.

Our research has allowed us to identify pro-allergenic cells, such as Th2A –T helper cells that are involved in the production of IgE (immunoglobulin E, antibodies produced by the immune system when it reacts to certain substances) as a therapeutic target for AIT.

Clinical development and real-world studies

Stallergenes Greer has conducted many clinical studies, involving more than 9,000 patients, to evaluate the safety and efficacy of our AIT treatments, and to produce high-quality data for decision-making.

A real-world approach is also increasingly being used by Stallergenes Greer. The Group currently has five real-world studies underway: BREATH, EfficAPSI, CORAP, MaDo and Practis. To learn more, refer to the Social section of this report.

A collaborative approach to innovation

Stallergenes Greer leverages open innovation to continue to advance precision medicine for the benefit of patients and healthcare practitioners.

The Group recently entered into research collaborations with: Imperial College London, on the discovery of biomarkers of AIT efficacy; Alyatec, a contract research organisation based in Strasbourg University Hospital (France), on allergy pathophysiology and endotypes; and the Swiss Institute of Allergy and Asthma Research (SIAF).

What we do

Technical operations

Our teams work around the clock to make sure that patients and healthcare practitioners receive the highest quality diagnostic solutions and allergen immunotherapy treatments.

Products derived from living systems

Like other biologic drugs, Stallergenes Greer's allergens are derived from living systems. Biologic drugs contain one or more active substances which are produced in a living system such as micro-organisms and plant or animal cells[1]. Biologics consist of large and complex molecules; their characterisation is challenging and involves highly advanced technologies.

A patient-centric approach

Because Stallergenes Greer's allergen immunotherapy (AIT) treatments cater to the real needs of patients, product design begins with a clear understanding of patient profiles: to which specific allergen is a patient exposed, to which allergen(s) is a patient sensitised and is the allergen clinically relevant.

Quality, safety, controls at every stage

To provide patients with the benefits they need, controlling the quality of allergen products is of prime importance to guarantee both the safety and efficacy of allergy diagnosis and treatment and consistent optimal clinical benefits[2].

Stallergenes Greer's allergens are manufactured in a living system and their production is strongly process-dependent. To ensure batch-to-batch consistency, quality and purity, we have established stringent controls of the source and nature of the source materials and apply hundreds of process controls to ensure that target quality attributes are delivered. Each batch of product is the combination of the product, documentation and controls.

Consistent biological potency through process standardisation

Stallergenes Greer ensures the consistent biological potency of its tablets, sublingual and subcutaneous products through standardised and validated quantitative analytical methods which assure the uniformity and purity of the Group's products and their activity.

Driving operational excellence

We seek excellence in every part of our organisation. Our approach to manufacturing quality products relies on continuous learning and improvements to ensure we are modernising our quality controls and improving our processes through investments in our facilities.

Having the right product available is critical to ensuring patient needs. We rigorously manage our operations to ensure product availability by focusing on operational excellence and investing in state-of-the-art equipment, technology, and systems.

1. Biological product definitions www.fda.gov -

2. Zimmer J, et al. Standardization and regulation of allergen products in the European Union. Curr Allergy Asthma Proc 2016;16(3):21

Year in review

NORTH AMERICA

Focus on quality and operational excellence yield strong performance

Stallergenes Greer North America posted double-digit organic growth in 2022, reflecting our commitment to excellence and our track record of successfully delivering high-quality products to customers.

Continued growth of our veterinary business

Our veterinary business experienced robust growth in 2022, with sales growing double-digit against the prior year. During the year, we successfully launched www.petsgetallergies.com, a website to raise awareness among pet owners that the signs their pet is showing may be due to allergies and that there are several options for treating them, including allergen immunotherapy. The objective of the site is also to help visitors learn about veterinary dermatologists who specialise in treating allergies and, ultimately, reach out to a veterinary dermatology practice to find out how they may be able to help them and their pet. In an effort to drive pet owners that have pets with potential allergies to this website, we also launched a pet owner social media campaign on both Facebook and Instagram.

The year also marked the return of in-person exhibiting following the pandemic. Stallergenes Greer attended the 2022 edition of the North American Veterinary Dermatology Forum (NAVDF) and sponsored a "residents' day" prior to the full conference.

Putting patients first

At Stallergenes Greer, serving patients is our top priority. Throughout the year, we maintained investments in our North American operational infrastructure, technology and people to deliver the high-quality bulk allergen extracts, named patient prescriptions and veterinary treatment solutions that our customers deserve.

Stallergenes Greer North America is engaged in a multi-year scale-up to continuously improve the flexibility of operations at its Lenoir (NC, U.S.) facility. Investments include equipment and software to increase efficiency, production quality and output, and reproducibility of our processes. The quality-focused culture of our teams was also reinforced by leadership management training, skills development training, project management and lean six sigma programs.

Meeting increased market demand for high priority allergens

Our double-digit year-on-year growth in North America bears witness to Stallergenes Greer's superior customer service, comprehensive portfolio of standardised and non-standardised allergen extracts, and legacy of commitment to the specialist community. Stallergenes Greer maintained positive supply and met the sharp increase in demand for allergen extracts by delivering high priority allergens when they were in short supply. Our San Diego (CA, U.S.) facility, for example, significantly increased the production of house dust mites to ensure supply for patients and the medical community.

Strengthening our integrated approach to source material supply

Stallergenes Greer recently reinforced its internal supply capabilities by purchasing more than 22 hectares of land to produce pollens in Mathiston (MS, U.S.). The acquisition contributes to both de-risking and ensuring greater control of the Group's supply chain, by reducing the reliance on third-party pollen collectors.

By growing and harvesting our own pollens we also gain better command of the different factors involved in harvesting to produce the purest pollens while enabling the harvesting of pollens that other collectors may not be able to obtain for us. It also provides the opportunity to test-grow new pollens for the benefit of our patients over the long-term. We currently grow, harvest, and collect over 75 different pollens in Mathiston.

Providing training to healthcare professionals

Stallergenes Greer provides training for healthcare professionals regarding pharmaceutical compounding and sterile preparations under Chapter 797 of USP (U.S. Pharmacopeia). USP, a non-profit organisation, establishes documentary and reference standards for medicines, food ingredients, dietary supplement products and ingredients which are used by U.S. regulatory agencies to help ensure that the forementioned products are of the appropriate identity, strength, quality, purity, and consistency. Each year, at the American College of Allergy, Asthma, and Immunology (ACAAI) Stallergenes Greer trains physicians regarding the guidelines which must be followed for aseptic preparation and compounding.

Canada, set for growth

In 2022, our Canadian affiliate continued to transform and invest in its quality systems to maintain excellence in quality assurance. The objectives were to: instil a quality mindset throughout the organisation, ensure we were properly resourced with qualified personnel, continue to enhance our quality management system incorporating good manufacturing practices (GMP), quality risk management and monitoring procedures and conduct robust shipping and temperature mapping studies. All the objectives were met at the end of 2022 and management will continue to build upon this transformation in the future.

The Canadian organisation also pursued the deployment of talent development plans to prepare top talent for their next role, ensure succession planning to accommodate future growth, provide a great place to work and retain top talent.

EUROPE AND INTERNATIONAL

Strong growth across markets and products

The Europe and International region continued on its growth path during 2022 and maintained market leadership in more than half of the 37 countries in which it is actively present.



In 2022, Stallergenes Greer's Europe and International operations achieved substantial performances with double-digit sales growth, market share gains across the product portfolio, and the introduction of Orylmyte®/Actair®, the Group's sublingual house dust mite allergen immunotherapy (AIT) tablet, in Europe.

To accompany our growth and geographic expansion, the Group significantly increased its sales force headcount in the region, notably in Germany, Italy, Poland and Spain.

Maintaining leading positions across our markets

In Germany, the largest AIT market worldwide, Stallergenes Greer became the fastest-growing company in the AIT space in terms of new patient initiations and sales value[1]. The German market is undergoing structural change subsequent to the Therapy Allergen Ordinance (TAO), announced in 2008 and which will end in 2026, which ensures that only registered and clinically proven allergen treatments will remain on the market. With the launch of Orylmyte®, Stallergenes Greer is currently one of the players to offer a fully registered evidence-based AIT portfolio for key allergens.

In Russia, our Staloral® mugwort study is finalised and registration submission is in preparation to expand our offering. Throughout the year, we made all efforts in countries affected by the geopolitical situation to ensure supply continuity for our patients.

In Italy and Spain, Stallergenes Greer gained market share in a slack environment. In North Africa, Staloral® obtained reimbursement in Tunisia, and in Morocco operations have restarted following the selection of a new distributor.

In Australia and South Korea, our house dust mite and grass AIT sales are on the rise following the launch of a new marketing campaign.

Helping healthcare professionals master the patient journey

With our portfolio of diagnostics, treatments and wider support programmes, Stallergenes Greer helps healthcare professionals make a meaningful difference by delivering optimal solutions and supporting them throughout the patient journey to improve the quality of life of allergy sufferers.

At Stallergenes Greer we believe that the AIT value proposition is to provide early onset of action, significant improvement of quality of life, and a carry-over effect after treatment cessation to modify the allergic disease progression. Our knowledge of AIT is supported by clinical trials, real-world evidence data and exploratory research. We favour precision and personalisation in AIT treatments adapted to the profile and needs of each patient in terms of flexibility and ease-of-use.

Expanding our geographic footprint

2022 was a year of geographic expansion for the Europe and International region with product launches and the restart of operations in several countries.

During the year, Stallergenes Greer made its first steps in the Croatian market with Actair®; relaunched its affiliate in The Netherlands with Oralair®, its tablet for grass allergies, and will soon introduce its house dust mite-allergy tablet Actair®.

In the Nordics region, Stallergenes Greer obtained the positive outcome of the repeat use mutual recognition procedure (MRP) for its sublingual grass pollen allergen immunotherapy tablet. To date, national marketing authorisations have been granted in Norway and Sweden. Stallergenes Greer aims to market both its grass and house dust mite tablets in Denmark, Norway and Sweden. Our grass tablet will be launched in Finland in the near future.

The Group continued to make progress towards entering the Chinese market, notably with regard to data generation for regulatory purposes. China, with a current AIT market value of over €100 million[2], which is expected to reach more than €1 billion in 2030[3], represents a significant potential growth driver for Stallergenes Greer.

Orylmyte®/Actair® available in eight European countries

After receiving a positive decision in 2021 from the Paul-Ehrlich-Institut (Germany), which acted as reference member state on behalf of 21 European countries, Stallergenes Greer's house dust mite AIT tablet was already available in eight European countries in the Europe and International region at year-end 2022: Austria, Bulgaria, Croatia, Czech Republic, Germany, Romania, Slovakia, Slovenia.

Growing our talents

Because our people are the cornerstone of our success, we continued to develop agile ways of working to drive efficiency and impact. In 2022, in addition to existing initiatives such as mentoring, coaching, apprenticeship, and project development assignments, which contribute to talent development and retention, and to succession planning, we expanded our range of talent development tools with internally developed training programmes for sales representatives and their managers.

By accompanying our people, we aim to empower individuals to make a sustainable contribution to patients and the medical community while creating a competitive advantage for the Group.

1. IQVIA Insight Health, Based on New Patients (Produkt-naiv), YTD/10/2022; Net Sales, YTD/11/2022 - 2. EIU report on China AIT market status and potential - 3. AIT market forecast and Actair NPV analyses 2019-2029

FRANCE

A pivotal year marked by significant innovations

In a sluggish economic environment, Stallergenes Greer continued to make strides in the French allergen immunotherapy (AIT) market with impactful innovations dedicated to improving treatment outcomes for patients with allergies.

Orylmyte®, an additional treatment option for house dust mite allergies

It is estimated that one third of the French population suffers from allergies and that more than half of allergy sufferers are sensitised to house dust mites[1]; house dust mites are one of the main causes of allergic rhinitis[2].

Launched on the French market at year-end 2022, our Orylmyte® sublingual tablet is the only house dust mite AIT tablet with dose escalation. It is composed of standardised allergenic extracts of house dust mites identical to our named patient products (NPPs), which benefit from more than 30 years of experience in treating young and adult patients with house dust mite allergies. Orylmyte® allows a gradual dose increase, acts from the first months of treatment and has demonstrated efficacy on allergic rhinitis symptoms and improves quality of life. Stallergenes Greer is in a position to offer a franchise of liquid and solid formulations, with the same allergenic extracts, to treat house dust mite and grass allergies with Orylmyte®, Staloral® house dust mite, Oralair® and Staloral® 5 Grasses.

iPUMP: innovation at the heart of our R&D

Because non-adherence to treatment remains a challenge in AIT management, our teams, in partnership with Aptar Pharma, developed iPUMP, a connected system in AIT. This connected system was developed to improve observance and adherence, thus improving the patient journey and optimising treatment outcomes.

This innovation further illustrates Stallergenes Greer's commitment to build on precision medicine and personalised healthcare to meet the needs of both patients and the medical community. It is also a demonstration of the ability of our teams to bring new products to market and continuously develop their skills and expertise in areas such as innovation, product development, quality, and safety for the benefit of all stakeholders.

Staloral® Cat 300IR, committed to fulfilling unmet medical needs

Allergic rhinitis attributable to cat dander has been increasing steadily with 30.5% of patients who suffer from allergic rhinitis sensitised to cat dander[3]. The allergen is found throughout the house (bedding, rugs, and carpets), is present in the air and can also be carried by clothing and shoes. Cat dander can be found in significant quantities even in a place where no cats live, such as a classroom. When allergy to cat dander is diagnosed, first-line treatment consists of eviction measures, however, this is rarely feasible considering the pervasiveness of this allergen.

Bringing new treatment solutions for these patients has been a priority for Stallergenes Greer and since its launch, Staloral® Cat 300IR has posted strong and steadily increasing sales. This performance confirms that this patient segment is largely underserved and contributes to confirming an unmet medical need in the field of allergies to cat dander.

EfficAPSI, real-world studies deliver public health value

In 2022, Stallergenes Greer published positive results from its efficAPSI real-world study which confirmed the significant benefit of sublingual liquid AIT treatment on the onset and worsening of asthma in patients with allergic rhinitis. Study results were consistent across all age groups (patients above the age of 5), allergens and endpoints.

EfficAPSI is the first study in the AIT field in which the French national system database (SNDS), covering 99% of the French population, has been used to gain insight on therapeutic benefits in real life practice by pairing their data with the data of a healthcare company. More than 400,000 patients were included in the study, the largest of its kind to date.

Progressing our digital transformation

In 2022, the French affiliate continued to move forward on its digital transformation. Important steps were taken regarding the digitalisation of patient services notably customer relationship management (CRM) for NPP prescriptions. By handling prescriptions digitally, from start to finish, we optimise the use of paper and printing, improve processing lead time, and gain better control of the process flow. The upgraded CRM tool allows patient service teams to rapidly visualise the information necessary to exchange with patients and answer any questions they may have regarding their treatment, while ensuring compliance with quality requirements, pharmaceutical regulations, controls and data protection.

Supporting RNSA: contributing to improving care pathways

Stallergenes Greer continues to work alongside patient associations and organisations to increase awareness about respiratory allergies. We recently unveiled a study carried out with RNSA, the French national aerobiology network in charge of the analysis of the content of biological particles, on the evolution of pollen data over a 10-year period. The study highlights both the variability of seasons which affects the symptomatology of allergy sufferers either earlier or later in the seasons, and an increase in pollen counts. Observations suggest that climate change has an impact on the allergenic potential of pollens and on the duration of symptoms. The dissemination of the data collected by RNSA will help healthcare professionals correlate allergy symptoms to the pollination of the various triggering allergens and better manage their allergic patients.

1. Rancé F, Juchet A, Brémont F, Dutau G. Répartition des sensibilisations dans l'asthme de l'enfant en fonction de l'âge. Corrélations avec les données cliniques et fonctionnelles respiratoires. Rev Fr Allergol Immunol Clin. 1997;37(2):160–166 - 2. Bousquet J, Khaltaev N, Cruz A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr; 63 Suppl 86:8-160. - Brozek JL, Bousquet J, Agache I, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) Guidelines - 3. ANSES (French Agency for Food, Environmental and Occupational Health and Safety). State of knowledge on the health impact of exposure of the general population to pollens in ambient air. Collective expertise report. January 2014

OUR CORPORATE RESPONSIBILITY COMMITMENTS

CARE BEYOND ALLERGY

FOR STALLERGENES GREER, 2022 MARKED THE REDEFINITION, WITH THE SUPPORT OF OUR LEADERSHIP, OF OUR CORPORATE RESPONSIBILITY PRIORITIES. *CARE BEYOND ALLERGY*, OUR CORPORATE RESPONSIBILITY PROGRAMME, REFLECTS OUR CONTRIBUTION TO BOTH OUR STAKEHOLDERS AND TO SOCIETY AS A WHOLE.

This chapter illustrates the key elements of Stallergenes Greer's corporate responsibility approach: the ethical principles which guide our Group, main corporate responsibility priorities, actions which have already been implemented, as well as the methodology used to build our corporate responsibility strategy.

01/ SOCIETY

"Patient needs drive our innovation to fight against all kinds of allergies"

encompasses our commitment to advancing scientific knowledge and working with healthcare professionals and patients to improve quality of life for people with allergies.

02/ ENVIRONMENT

"We are committed to advancing climate action and preserving nature to boost the prevention and treatment of allergies"

illustrates our engagement to address our environmental impact on the value chain and contribute to supporting research in environmental health.

03/ SOCIAL

"Investing in our people and empowering them to unleash their full potential"

reflects our responsibility towards the well-being of our people and encouraging their success and development.

04/ GOVERNANCE

"Building trust with our stakeholders every day"

embodies our commitment to uphold high ethical standards and conduct our business with integrity.

Stallergenes Greer's approach is aligned with the Group's strategic positioning.

Four pillars form the framework of our corporate responsibility programme, *Care Beyond Allergy*. They emphasise our responsibility both as a company and as an employer and focus on areas in which we can make a difference.

CARE BEYOND ALLERGY
A PROGRAMME BUILT WITH OUR STAKEHOLDERS

The construction of our corporate responsibility programme began in 2021 with a maturity assessment regarding the status of the Group's approach towards social, societal, environmental, and governance issues as defined by ISO 26000 and the 17 United Nations Sustainable Development Goals (SDGs). More than 11 hours of interviews and 90 questionnaires, covering the 35 corporate responsibility challenges, were studied. The methodology used by Stallergenes Greer, derived from the LUCIE 26000 and AFNOR (AFAQ 26000) frames of reference, allowed us to establish that the Group's contribution to these challenges was positive.

In 2022, Stallergenes Greer then conducted a materiality analysis to identify and prioritise the corporate responsibility challenges that it will face up to 2030. This analysis combines the vision of internal stakeholders with the vision of external stakeholders to identify material issues on which the Group should focus its efforts.

The materiality matrix, developed in compliance with the recommendations of the Global Reporting Initiative (GRI) and the International Integrated Reporting Framework (IR Framework), guides our policy regarding corporate responsibility initiatives.

The first step in the process was the identification of 35 challenges which Stallergenes Greer faces as a pharmaceutical company. Sources such as the guiding principles of GRI-4, the 10 principles of the Global Compact, the 15 guiding principles of the OECD (Organisation for Economic Co-operation and Development), the 17 SDGs, the seven central issues covered by ISO 26000, as well as challenges specific to the pharmaceutical sector and regulations in progress regarding non-financial indicators were consulted to establish this list.

The construction of Stallergenes Greer's corporate responsibility programme involved senior management, executives and external stakeholders who engaged in a series of workshops, online questionnaires, and interviews regarding the 35 challenges identified.

Close to 200 people were consulted in the process and 24 hours of interviews were held to gather and share the expectations of employees, patients, healthcare professionals and public authorities.

The significance of each issue was then assembled on a materiality matrix according to the level of expectation of our stakeholders. The matrix was subsequently refined during a workshop with representatives of Stallergenes Greer's main functions.

This process and the data collected enabled Stallergenes Greer to produce its materiality matrix while collecting valuable qualitative information concerning the perception that its stakeholders have of the Group's current corporate responsibility commitments and future challenges.

Close to 200 people were consulted in the process and 24 hours of interviews were held to gather and share the expectations of employees, patients, healthcare professionals and public authorities.

STAKEHOLDER EXPECTATIONS



SOCIETAL ISSUES
GOVERNANCE ISSUES
ENVIRONMENTAL ISSUES
SOCIAL ISSUES

PRIORITIES

1. Patient security
2. Patient supply
3. Health and safety at work
4. Responsible management
5. Services to patient
6. Pollution
7. Risk management
8. Environmental health
9. Innovation with impact
10. Quality of life at work
11. Access
12. Professional development
13. Responsible procurement
14. Human dignity
15. Stakeholder engagement
16. Climate

OTHER ISSUES

17. Strategic CSR
18. Corruption
19. Diversity
20. Natural resources
21. Product information

Through *Care Beyond Allergy*, Stallergenes Greer participates in the global effort to reach the United Nations Sustainable Development Goals (SDG) as set out in the United Nations' 2030 Agenda for Sustainable Development. The Group's corporate responsibility programme more specifically targets 11 of the United Nations' SDGs:

01/ OUR COMMITMENT TO SOCIETY

AT STALLERGENES GREER "PATIENT NEEDS DRIVE OUR INNOVATION TO FIGHT AGAINST ALL KINDS OF ALLERGIES".

The societal pillar of our corporate responsibility approach includes four key programme commitments which contribute to better meeting the needs of patients and healthcare professionals by fostering innovation and collaboration.

ONE/

ACCELERATE RESEARCH TO OFFER A COMPREHENSIVE PORTFOLIO OF INNOVATIVE AND PERSONALISED SOLUTIONS AGAINST ALLERGIES

Investing in real-world studies

Stallergenes Greer has conducted a large number of clinical studies, involving more than 9,000 patients. Real-world studies, which include larger patient populations and better reflect "real life" patient profiles, are also used by Stallergenes Greer to further evidence allergen immunotherapy (AIT) treatments beyond clinical trials.

In 2022, Stallergenes Greer announced positive data from its EfficAPSI study, the largest retrospective real-world, longitudinal cohort study regarding sublingual liquid AIT. Its objective is to evaluate the real-life impact of sublingual liquid AIT on the onset and worsening of asthma in patients with allergic rhinitis. This study included more than 100,000 patients in France with allergic rhinitis, with or without asthma, treated with sublingual liquid AIT and symptomatic drugs, and more than 330,000 patients with allergic rhinitis, with or without asthma, treated with symptomatic drugs only.

Including EfficAPSI, Stallergenes Greer has five real-world studies underway: BREATH launched in 2017 (to evaluate the efficacy of sublingual AIT tablets), CORAP (to evaluate the impact of AIT on the quality of life of patients); MaDo (to retrospectively analyse the needs and impacts of AIT dose adjustment); and PRACTIS (to evaluate the benefits of sublingual AIT in current practice according to the different methods of use and the type of allergen).

A collaborative approach to innovation

Stallergenes Greer leverages open innovation to continue to advance precision medicine for the benefit of patients and healthcare practitioners. In 2022, new research collaborations focusing on the identification of biomarkers of AIT efficacy were initiated with world-leading organisations such as Imperial College London and the Swiss Institute of Allergy and Asthma Research (SIAF). These collaborations will deepen knowledge of the pathophysiology of allergic diseases and the biological effect of AIT, and their results could be applied in the routine practice of allergology. Additional collaborations are ongoing, such as the one with Alyatec, a contract research organisation (CRO) based in Strasbourg University Hospital (France), which leverages the CRO's new generation environmental exposure chamber to assess the mode of action of allergy treatment solutions.

iPUMP: a connected AIT delivery system

Because non-adherence to an AIT schedule and premature discontinuation of treatment remain a challenge in AIT management, Stallergenes Greer, in partnership with Aptar Pharma, developed iPUMP. iPUMP is a connected drug delivery system and companion mobile app aimed at improving observance and adherence to optimise patient treatment outcomes. The development of iPUMP illustrates our investments in innovation to provide a large range of precise personalised AIT options adapted to the needs and lifestyle of patients. After a pilot phase during which patients will test the system, our aim is to make iPUMP available in France in 2023 and to progressively roll out in other markets.

We are driven to advance allergy care treatments and delivery modes.

We work with patients and the medical community to better meet their needs, and establish collaborations with leading organisations to develop cutting edge technologies and progress scientific knowledge.

Our contribution to the UN SDGs

9,000 PATIENTS INCLUDED IN CLINICAL STUDIES

TWO/

CONTRIBUTE TO GATHERING SCIENTIFIC AND MEDICAL KNOWLEDGE ON ALLERGIES AND THE SOCIOECONOMIC IMPACT OF AIT

Sustaining our philanthropic efforts

Advancing allergy care and scientific knowledge for the benefit of allergy sufferers and the medical community are part of our DNA. In early 2023, we relaunched the Stallergenes Greer Foundation, which was created in 2013, to further strengthen our engagement towards our stakeholders via a long-term philanthropic approach. Learn more about our foundation in the dedicated section of this report.

Engaging with global health experts and raising awareness about allergies

Participating in scientific congresses allows for essential scientific exchange on the latest research and gaining insight from healthcare professionals while contributing to improve how we develop and deliver our AIT treatments to patients and the medical community.

In 2022, Stallergenes Greer participated and/or sponsored, four international congresses (EAACI, ACAAI, APAAACI and ANACARE) and 20 local ones.

We also continued to develop our online conferences and webinars for healthcare professionals to share information, recommendations and scientific updates in the field of allergology. Our Stall'Web conferences were attended by more than 200 physicians in 2022.

Since 2019, Stallergenes Greer organises annual AIT training sessions, Go Beyond, hosted by key external experts for young healthcare professionals with the aim of contributing to the dissemination of knowledge about allergy care pathways and sharing best practices to enhance patient care.

FIVE REAL WORLD STUDIES

THREE/

ENSURE PATIENT SECURITY AND TREATMENT SUPPLY

Sustained investments in our industrial tool

Over the past years, we have made continuous improvements to our manufacturing capabilities, both in France and the U.S., to maintain manufacturing and quality systems that meet the highest product quality and security standards.

In 2022, our Antony (France) facility introduced a state-of-the-art packaging line for Staloral® to upgrade its production assets. The line improves the overall reliability of the packaging process while ensuring the supply remains uninterrupted and the packaging capacity secure.

Securing our supply chain

We have adopted an integrated approach to the sourcing of our raw materials, the production of our treatments and their distribution. For house dust mites we grow the two key species responsible for allergies: *Dermatophagoides farinae* (American house dust mite) and *Dermatophagoides pteronyssinus* (European house dust mite) at our Antony (France) site.

For grass, we grow, harvest and purify five species of grasses (cocksfoot, sweet vernal grass, rye grass, meadow grass, and timothy) on 90 hectares of land in Amilly (France) which represent many of the natural exposure and sensitisation conditions of grass-pollen allergic patients.

In the U.S., our Mathiston, Mississippi, facility grows, harvests and collects over 75 different types of pollen on more than 56 hectares of land. For mould, the mycology department in Lenoir (North Carolina) prepares fungi for extraction and can grow more than 60 different fungal cultures. To assure long-term supply and safety stock, we maintain stock cultures of our moulds, stored as either oil overlays or lyophilised plugs.

430,000 PATIENTS IN OUR EFFICAPSI REAL-WORLD STUDY

FOUR/

JOIN EFFORTS WITH PATIENTS AND PRACTITIONERS TO ENHANCE THE QUALITY OF LIFE OF ALLERGY SUFFERERS AND IMPROVE THE PATIENT JOURNEY

Including the patient's voice

We are committed to understanding the needs of patients. We ensure that their voice is included in our decisions by collaborating with patients and patient associations for the development of innovative products or services, such as iPUMP, and in our research programmes.

For example, our CORAP programme, which evaluates the impact of AIT on the quality of life of patients, directly involves patients in Stallergenes Greer's research projects. The programme includes a research plan which aims to provide additional knowledge about the various types of respiratory allergies via clinical projects and real-world data. Patients undergoing our AIT treatments can join the CORAP community, on a voluntary basis, and participate in the various stages of our research initiatives.

Digitalisation of patient services to improve ease of use

In France, following the implementation of our OrdoApsi platform which aims to facilitate the prescription flow, a new generation CRM (electronic management of patient documents and order flow) was implemented in 2022. The objective of the CRM is to track each step of treatment orders for named patient products to better respond to any questions patients may have, from the creation of the administrative file for third-party payment to the delivery of the treatment.

Developing patient resources

Because there are many things online about allergies and how they can be treated, it can sometimes be difficult to navigate the profusion of information and, more importantly, confirm that it is accurate. To assist patients with allergies and healthcare professionals, Stallergenes Greer launched the AIT Network (www.theaitnetwork.com). Developed, in partnership with a group of external scientific experts, the AIT Network is an educational platform where users can find scientifically credible educational content and up-to-date news on allergies.

In France, our personalised patient support programme launched in 2021 improves the patient's follow up with dedicated calls to patients and targeted emails throughout the treatment journey. 1,690 patients have already subscribed to this tailored support service. In the U.S., Stallergenes Greer launched www.petsgetallergies.com to raise awareness among pet owners that the signs their pet is showing may be due to allergies. Pet owners can also use the Veterinary Dermatologist Finder to locate a specialist near them so that they can easily reach out to them and initiate a conversation about their pet.

"Ensuring the safety, efficacy and high quality of our AIT treatments is a priority. We are committed to joining efforts with physicians, experts and cutting-edge organisations to push the boundaries of science for the benefit of patients."

AMER JABER
Executive Vice President, Operations Europe

02/ OUR COMMITMENT TO THE ENVIRONMENT

AT STALLERGENES GREER "WE EMBRACE THE PROTECTION OF CLIMATE AND NATURE TO BOOST THE PREVENTION AND TREATMENT OF ALLERGIES".

The environmental pillar of our corporate responsibility approach includes six key programme commitments which illustrate our engagement to address our environmental impact on the value chain and contribute to supporting research in environmental health.

ONE/

SUPPORT OUR SITES IN ADJUSTING TO ENVIRONMENTAL CHALLENGES

Environmental considerations included in all PMO initiatives

To ensure that environmental considerations are taken into account by the teams in the design and development of Stallergenes Greer's strategic projects, a specific module was tailored into our portfolio management software to help project managers define how each project contributes to the objectives of our corporate responsibility strategy. The environmental impact assessment will also be integrated into the preparation of the business case before project launch.

Local environmental advisors monitor and progress our actions

In 2023, a global environmental advisor will be appointed to ensure compliance with regulations pertaining to environmental management and provide recommendations regarding water, waste, land and air quality management. In liaison with the Group's Corporate Responsibility Committee and local management, the advisor will also provide support to the project management teams.

Green Team volunteers show the way

Green Teams are in the process of being set up to help drive Stallergenes Greer's sustainability efforts. Composed of volunteers, the Green Teams will focus on reducing the day-to-day environmental footprint of our offices through projects which aim to reduce and recycle office waste, source environmentally friendly office supplies, or lessen energy consumption via the use of LED lights, for example. Thanks to our Green Teams, eco-gestures will be reinforced across all our offices.

We are committed to mitigating the environmental impact of our business operations and supply chain and using natural resources responsibly.

Because the quality of the air we breathe has a significant impact on the health of populations across the globe, we also support research initiatives in the field of environmental health and aim to raise awareness regarding climate action.

Our contribution to the UN SDGs

SEEK ENERGY EFFICIENCY

TWO/
CONTRIBUTE TO THE OBJECTIVES OF THE PARIS AGREEMENT

Understanding our greenhouse gas impacts

In 2022, Stallergenes Greer took important steps to understand its climate impacts. Our direct greenhouse gas emissions are generated by our production facilities and offices, while indirect emissions are primarily related to employee commuting, travel, and the distribution of our treatments.

Work regarding the collection and estimate of our carbon emissions (scope 1 and 2) is ongoing. We will continue to assess how to reduce our greenhouse gas emissions and develop Group-wide targets which will be disclosed next year.

Green mobility practices

Operating our business involves business travel, to establish and maintain strong relations with our partners and colleagues, as well commuting to and from our offices daily. As previously stated, Stallergenes Greer is currently assessing its environmental impact, however, steps have already been taken to reduce carbon emissions from business travel. The Group promotes the use of digital solutions and collaborative tools, the fleet of company cars will be progressively replaced with models which pollute less and charging stations for electric vehicles will be deployed across our main sites.

In Antony (France), to further limit the environmental impact linked to commuting, employees can already benefit from a sustainable mobility subsidy allocated for the use of a mechanical or electrically assisted bicycle.



THREE/
USE NATURAL RESOURCES RESPONSIBLY

Energy efficiency

Stallergenes Greer has already implemented a series of initiatives across its different sites to become more energy efficient. In Antony (France), our approach covers areas such as the progressive implementation of LED lighting in all our buildings, reducing the time during which our signage is lit, controlling and programming heating temperatures and promoting the use of environmentally friendly practices daily for water and electricity consumption, or waste management. In Lenoir (NC, U.S.), lean energy initiatives include air leak reduction, steam leak reduction, changing lighting fixtures to LED, water leak reduction, and various other electrical energy items. The site is also working to connect all HVAC (Heating, Ventilation and Air Conditioning) systems in non-critical areas to the building automation system that will have programmable schedules to set back temperatures when areas are unoccupied.

Working with nature

Our allergen extracts are derived from natural sources, and we have adopted an integrated approach to the sourcing of most of our raw materials to ensure their availability and reproducibility. In France, our Amilly site, grows five species of grasses (cocksfoot, sweet vernal grass, rye grass, meadow grass, and timothy) on 90 hectares of land. In the U.S., our Mathiston, Mississippi, site grows harvests and collects over 75 different types of pollen on more than 56 hectares of land. The land is maintained by Stallergenes Greer and relies on natural processes to build soil fertility.

FOUR/
IMPLEMENT ECO-FRIENDLY PACKAGING SOLUTIONS

Stallergenes Greer uses paper, cardboard, plastic for the packaging and/or transport of its treatments and is currently assessing methods and suppliers to shift to more sustainable materials.

The use of sustainably sourced and recycled materials in our packaging materials is one of our objectives. The Group's new packaging line in Antony (France), which was implemented in 2022, is capable of processing recycled materials.

FIVE/
INCREASE AWARENESS ON ENVIRONMENTAL CHALLENGES

Partnering with organisations

Stallergenes Greer France has been partnering with RNSA, the national aerobiology network in charge of the analysis of the content of biological particles, for several years now. An RNSA sensor was installed on our Antony site in 2013 to study the content of biological particles in the air (pollens, moulds) that may have an impact on the allergic risk of individuals and collect the associated clinical data.

Stallergenes Greer and RNSA also recently unveiled the results of a study on the impact of climate change on pollens in France and on the environment in which allergic people live. To know more about the study, refer to the Operating Review France section of this report.

GREEN TEAMS HELP DRIVE SUSTAINABILITY

SIX/
SUPPORT RESEARCH IN ENVIRONMENTAL HEALTH AND ECOLOGY OF HEALTH, WITH A SPECIFIC FOCUS ON THE IMPACT OF AIR POLLUTION ON RESPIRATORY DISEASES

Through the Stallergenes Greer Foundation, we will sponsor research efforts in the field of respiratory airway diseases and thus contribute to the One Health initiative dedicated to improving the lives of all species. Philanthropic actions related to environmental matters may also be supported by the foundation.

"The environmental challenges we are all facing can only be tackled with the support, collaboration and commitment of all the teams across the organisation. We are taking proactive steps to generate sustainable practices which will create value for society as a whole."

NICOLA LAMACCHIA
Chief Financial Officer

ALLERGEN EXTRACTS DERIVED FROM NATURAL SOURCES

03/ OUR COMMITMENT TO OUR PEOPLE

AT STALLERGENES GREER "WE INVEST IN OUR PEOPLE AND EMPOWER THEM TO UNLEASH THEIR FULL POTENTIAL".

The social pillar of our corporate responsibility approach includes five key programme commitments which illustrate our responsibility towards the well-being of our people and our engagement to foster their success and development.

ONE/
BE A SAFE PLACE TO WORK

Strong safety performance

Health and safety in the workplace are paramount for Stallergenes Greer. In compliance with local laws and regulations, all our sites implement action plans and preventive measures applicable to both employees and onsite contractors. Our Occupational Health and Safety Charter guarantees a safe and healthy working environment for all and guides our practices.

In 2022, we reported less than 10 work-related accidents, representing a 50% decrease versus the previous year. Our Group-wide objective is to report 0 work-related accidents with lost workdays by 2025.

Implement an Environment, Health and Safety governance body

In 2023, Stallergenes Greer will implement a global Environment, Health, and Safety (HSE) committee to oversee all HSE issues and assess occupational health and safety measures. In 2023, in Antony (France) our the HSE committee will be supported by security correspondents in each of our buildings. They will be progressively appointed across the organisation.

"Stallergenes Greer's diverse and inclusive culture, where colleagues are respected for who they are, makes us who we are. Attracting, developing, and retaining people from all backgrounds makes us stronger."

JÉRÔME TILLY
Senior Vice President, Human Resources

We are committed to creating a safe work environment and the right conditions for our people to thrive and collaborate.

We celebrate the diversity of our colleagues, provide resources for continued learning and professional development, and encourage people to take initiative.

Our contribution to the UN SDGs

LEAN SIX SIGMA TRAINING PROGRAMME ACROSS THE ORGANISATION

TWO/
BE THE RIGHT PLACE TO WORK

Quality of life at work

In addition to the implementation of processes to prevent the arising of situations due to organisational constraints or to protect employees throughout the recent health crisis, we are committed to ensuring the well-being of our colleagues in the workplace. A Group-wide survey will be carried out to gather feedback on employee needs and expectations to further improve working conditions and employee well-being.

Work organisation

With the shift of work organisation brought by the pandemic, Stallergenes Greer has, when possible, implemented a flexible work organisation for its employees globally. In line with our ways of working, and to sustain work-life balance, managers and employees are responsible for establishing the optimal work organisation within their team (use of collaborative meeting tools, needs of colleagues for social interaction in the workplace, flexibility, etc.).

Our values

To strengthen the sense of purpose that guides our actions, in 2023, Stallergenes Greer will work on the development of corporate values. Our values will form the bedrock of our culture, drive how we do business, instil alignment across the organisation and contribute to our performance.

THREE/
INVEST IN TRAINING AND PROFESSIONAL DEVELOPMENT

Group-wide lean management training

To develop the growth of our people, we initiated a Group-wide “Lean Six Sigma” continuous improvement programme. The programme, coordinated by Stallergenes Greer’s Human Resources department and the Project Management Office, is being rolled out on all sites. The Lean Six Sigma training programme aims to help employees to gain skills in analysis and methodology, better assess situations and determine solutions, and implement and execute action plans.

Skills development courses for all employees

Our objective is for each employee to follow one training course per year in 2025, to maintain or develop the skills of each individual. The training programmes will focus on technical, organisational, managerial or individual development.

A 50% DECREASE IN WORK-RELATED ACCIDENTS IN 2022

FOUR/
UPGRADE OUR TALENT PROGRAMME TO ANTICIPATE TOMORROW’S MUST-HAVE SKILLS

Broadening leadership training

In 2021, Stallergenes Greer initiated a global talent management programme with INSEAD. The five-week training programme, “Developing Emerging Leaders”, focuses on management and leadership skills and is tailored to the various profiles and functions of the participants. Beyond skill and leadership development, the programme also aims to strengthen and develop a shared corporate culture and participants will be included in the thought process to build the future of Stallergenes Greer. To date 36 colleagues from eight countries have already received their diploma and the programme will be broadened to an increasing number of colleagues going forward.

FIVE/
FOSTER A DIVERSE AND INCLUSIVE WORKPLACE

Mentoring people with disabilities

In 2022, our French affiliate initiated a pilot programme for the mentoring of people with disabilities at its Antony site. Colleagues volunteered to accompany and counsel persons with disabilities regarding their job search and share their expertise in their respective sectors. The duos were designed for the mentor’s area of expertise to match the mentee’s search profile. The pilot programme, which is ongoing, allows employees to lend a helping hand while providing an opportunity to engage with people from different backgrounds, exchange ideas and to open up to others.

Recruiting, developing, and retaining talents without any distinction

Individual differences make us stronger, and we are committed to fostering a culture where people are celebrated for who they are regardless of ability, ethnicity, race, religion, culture, gender, gender identity, sexual orientation and age. We aim to create a work environment where each person is respected and empowered to fulfil their potential.

36 EMPLOYEES FOLLOWED A GLOBAL TALENT MANAGEMENT PROGRAMME

04/ OUR COMMITMENT TO GOVERNANCE

AT STALLERGENES GREER "WE BUILD TRUST WITH OUR STAKEHOLDERS EVERY DAY".

The governance pillar of our corporate responsibility approach includes five key programme commitments which illustrate our commitment to maintaining the highest business standards and responsible business practices.

ONE/ DEPLOY A COMMITTED CORPORATE RESPONSIBILITY GOVERNANCE

Structure the management of our corporate responsibility programme and objectives

A dedicated committee was set up in 2021 to assess the Group's corporate responsibility maturity level and define the strategic orientations and objectives of Stallergenes Greer's policy.

Stallergenes Greer's Corporate Responsibility Committee comprises seven members of the Executive Committee, and the Head of Communication and Corporate Responsibility who chairs the committee. The Group's corporate responsibility programme is sponsored by the General Counsel who is also the Secretary to the Board of Directors. The committee ensures strategic alignment, coordinates action plans and is responsible for raising awareness and mobilising our colleagues on related issues.

Include corporate responsibility matters in strategic projects and project management training

Because corporate responsibility considerations must be addressed at the initiation of strategic projects, a module has been incorporated in our project management software (refer to the Environment section of this report) to notably address environmental issues. In addition, to raise awareness on topics pertaining to corporate responsibility and their importance, a specific training was developed for project managers.

To date, 23 managers have followed the dedicated training programme and the objective is for all project managers to complete the programme.

"Medicines contribute to preserving and restoring the most precious thing in life: health and quality of life. As a pharmaceutical company, we actively participate in the health and well-being of populations and take ownership of the responsibility that comes with it. It is our duty to be exemplary and act with a high degree of integrity."

VALÉRIE BENHAMOU
General Counsel

We are committed to conducting business with integrity, carrying out our operations in a responsible manner and we promote transparency and ethics in the way we do business.

Our corporate responsibility strategy is supported by our Executive Committee and our Board of Directors is regularly informed of its progress.

Our contribution to the UN SDGs

IN 2023, ROLLOUT OF A GROUP-WIDE CORPORATE RESPONSIBILITY AWARENESS PROGRAMME

TWO/

INTEGRATE SUSTAINABILITY AS A SHARED VALUE ACROSS THE ORGANISATION

Develop a corporate responsibility awareness programme for our people

We know that we can rely on our people to transform our corporate responsibility objectives into concrete actions on a daily basis.

To empower our employees to make a difference every day, in 2023, Stallergenes Greer will launch a Group-wide corporate responsibility awareness programme. Online sessions will be held each year to familiarise the teams with corporate responsibility, foster engagement on the topic and provide them with the skills and tools to become active participants in *Care Beyond Allergy*.

THREE/

INCLUDE ENVIRONMENTAL CRITERIA IN OUR RISK MANAGEMENT PROCESS

Environmental risk mapping

Because environmental change is a source of risks, Stallergenes Greer has included environmental risk in its mapping. A dedicated task force has been created to evaluate the Group's vulnerability to climate change (drought, heatwaves, etc.) as well as to transition risks (market, legal, etc.) and develop a mitigation plan.

Non-financial risk mapping will be updated every year.

FOUR/

IMPLEMENT A RESPONSIBLE PROCUREMENT POLICY

We are currently in the process of implementing a responsible procurement policy. Key steps include a corporate responsibility audit tool of our supplier database, the development of a correction plan to address potential deficiencies. A Responsible Procurement Charter will be drawn up and corporate responsibility principles will be included in future tendering process, including requests for proposals with the sheltered sector.

IMPLEMENTATION OF A RESPONSIBLE PROCUREMENT POLICY

DEVELOPMENT OF A THIRD PARTY ASSESSMENT POLICY

FIVE/

MAINTAIN HIGH STANDARDS BY CONDUCTING BUSINESS WITH INTEGRITY

Meeting high standards through strict policies and processes

Stallergenes Greer's *Code of Ethics and Business Conduct*, adopted by the Board of Directors, serves as a foundation for how we conduct business when performing our day-to-day job responsibilities. The *Code of Ethics and Business Conduct* promotes honest and ethical conduct among all individuals employed by or associated with Stallergenes Greer. Stallergenes Greer's *Code of Ethics and Business Conduct*, distributed to each employee, is available on the Group's intranet in eight languages and on Stallergenes Greer's corporate website.

Maintaining these high standards contributes to building trust with our partners and supports our performance. In addition to its *Code of Ethics and Business Conduct*, Stallergenes Greer has also developed and disseminated throughout the Group specific policies related to anti-corruption, antitrust, whistleblowing, conflict of interest, gifts and hospitality.

Compliance training for all

Stallergenes Greer provides numerous training courses to its employees, among them three specific compliance training courses, which are mandatory for all employees worldwide. All courses are validated by a quiz:

- *Conflict of Interest* in the US and *Anti-corruption* for the Europe and International region: to better understand our policy, and strengthen competencies required to avoid any actual or perceived risk of impropriety or corruption.
- *Gifts and Hospitality*: to better understand our policy. Role plays are used to comprehend its' application in concrete situations.
- *Code of Ethics and Business Conduct*: "reading" assistance to better comprehend the Code, its use and function.

These training courses must be carried out by each new employee within a month following his/her arrival. Renewal sessions are scheduled every two years by the IT department via our training platforms and must be completed within a two-month timeframe.

Implement a third-party evaluation screening platform

As part of its daily business, Stallergenes Greer collaborates, exchanges and works with third parties such as suppliers, agents, consultants, distributors, etc. We must remain vigilant and ensure the integrity of current and potential third parties. A *Third Party Assessment Policy* has been developed and an assessment platform will be progressively deployed, starting with the Europe and International region in 2023.

Data protection

Stallergenes Greer is a strong advocate of personal data protection, and we take careful steps to ensure that personal data protection rules and principles are applied to secure the trust we have built with our stakeholders. Our compliance programme serves as a framework to help comply with personal data protection laws. This programme, which includes policies, directives, procedures, and practical guides, is led by Stallergenes Greer's Data Protection Officer (DPO), who reports to the General Counsel. Quarterly reports are presented to the Board of Directors. E-learning platforms and in person data protection training modules on personal data protection have been implemented to raise large-scale awareness of our employees.

MANDATORY COMPLIANCE TRAINING FOR ALL EMPLOYEES

Stallergenes Greer Foundation

Stallergenes Greer Foundation

The Stallergenes Greer Foundation was relaunched in early 2023. Its mission is to “Create healthier futures for all”.

The Stallergenes Greer Foundation pursues a comprehensive approach calling for “the collaborative efforts of multiple disciplines working locally, nationally, and globally, to attain optimal health for people, animals and our environment”, as defined by the One Health initiative.

The Stallergenes Greer Foundation is under the aegis of the Fondation de France. Its actions are carried out transparently and respect our ethical commitments to the Fondation de France.

GOVERNANCE

Each member of the Stallergenes Greer Foundation brings unique expertise to contribute to achieving our mission of creating healthier futures for all.

The Stallergenes Greer Foundation is governed by a Board of Trustees which brings together the Managing Board and the Scientific Board.

Managing Board

The Managing Board is composed of four Stallergenes Greer executive officers.

Michele Antonelli, Chairman of the Stallergenes Greer Foundation; CEO, Stallergenes Greer

Amer Jaber, Scientific Director of the Stallergenes Greer Foundation; EVP Operations Europe and International, Stallergenes Greer

Catherine Kress, Secretary General of the Stallergenes Greer Foundation; Head of Communication and Corporate responsibility, Stallergenes Greer

Dominique Pezziardi, Strategy Director of the Stallergenes Greer Foundation; General Manager France, Belgium and Luxembourg - Global Head of Pricing and Market Access, Stallergenes Greer

Scientific Board

The Scientific Board is composed of four independent members.

Pascal Demoly, Professor of Pulmonology and Head of Department at the University Hospital of Montpellier (France)

Alessandro Fiocchi, MD, Director of Allergy at Pediatric Hospital Bambino Gesù, Rome, Vatican City (Italy)

Carla Irani, Associate Professor, Internal Medicine and Clinical Immunology, Allergology - Immunological Asthma at Hôtel Dieu de France University Medical Center, Beirut (Lebanon)

Kari Nadeau, MD, PhD, Chair of the Department of Environmental Health at Harvard T.H. Chan School of Public Health, Boston (MA, U.S.A.)

STALLERGENES GREER Foundation

FOCUS AREAS

The Stallergenes Greer Foundation aims to create healthier futures for all by focusing on three key areas.

Advancing scientific research to bolster innovation and precision medicine

By focusing on scientific innovation and research, the Stallergenes Greer Foundation aims to support the scientific community in furthering allergology research to discover and develop novel solutions for people with allergic diseases.

Supporting academic initiatives to further develop future generations of allergy healthcare professionals

Because the future of allergology is being prepared today, the Stallergenes Greer Foundation encourages and supports the emergence of innovative academic projects.

Engaging in climate action and environmental protection to progress the prevention and treatment of allergies

Because the quality of the air we breathe has significant consequences on our health and can exacerbate chronic respiratory diseases[1], the Stallergenes Greer Foundation is committed to raising awareness about climate change and environmental protection for the benefit of populations around the globe.

In 2023, the foundation will allocate up to 150,000 € for outstanding work led either by a young scientist or a mid-career scientist to advance precision medicine in the field of allergy, or outstanding work in the environmental field to advance the prevention and treatment of allergies.

ABOUT FONDATION DE FRANCE

Created in 1969, Fondation de France is a private organisation recognised of public interest, whose mission is to support all forms of generosity in order to translate them into effective actions of general interest.

With close to 1,000 hosted foundations, Fondation de France supports more than 10,000 promising and innovative initiatives in France and abroad each year.

Fondation de France is independent and private and operates thanks to the generosity of donors.

1. D'Amato G, Liccardi G, D'Amato M. The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy.

Stallergenes Greer portfolio

Our portfolio

Stallergenes Greer supports physicians specialised in allergy and patients at each stage of allergen immunotherapy treatment. Our comprehensive and consistent portfolio is adapted to the individual needs and profile of each patient and covers a broad variety of allergens.

Spanning source materials, routes of administration, cutting-edge delivery mechanisms and finished products, Stallergenes Greer's innovative diagnostic tools and allergen immunotherapy (AIT) solutions are designed to improve ease of access and treatment outcomes.

Whatever the options, Stallergenes Greer's diagnostic and AIT treatments meet the most stringent clinical criteria, quality standards and health authorities' regulatory requirements.

Named patient products

Stallergenes Greer believes one solution does not fit all patients, hence we provide patients with personalised treatment options that are tailored to their individual needs. We aim to offer a comprehensive portfolio of AIT treatments globally which allow patients and their physicians to determine the administration method that best meets the disease and lifestyle needs of the patient.

The Group's allergen extracts cover a vast array of allergens. They can be produced in standardised form and can also be tailored to the specific needs of patients in terms of composition, concentration, and dosage.

These personalised solutions, known as named patient products (NPPs), are prepared according to the physician's prescription and the patient profile using a stock solution obtained via the extraction of allergens (pollens, house dust mites, moulds...). Each NPP has its own biological activity and is prepared for the unique needs of an individual patient.

Sublingual

Staloral® (oral solution), for the treatment of allergy involving rhinitis, conjunctivitis, rhino conjunctivitis or asthma (mild to moderate) of a seasonal or perennial nature, in adults and children (from the age of 5).

Actair®/ Orylmyte®/ Aitmyte® (tablet), for the treatment of house dust mite allergies involving rhinitis, with or without conjunctivitis, in adults and adolescents over the age of 12 (and under 12 years of age in certain territories).

Oralair®/ Aitgrys® (tablet), for the treatment of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents, and children (above the age of 5). Oralair® is a five-grass (cocksfoot, sweet vernal grass, rye grass, meadow grass, and timothy) mixture, which represents many of the natural exposure and sensitisation conditions of grass pollen allergic patients.

Subcutaneous

Alustal®, for the treatment of allergic rhinitis, allergic rhinoconjunctivitis or mild to moderate asthma in adults and children (from the age of 5).

Albey® venom, for the treatment of allergy to wasp, honeybee, and yellow jacket venoms.

Extracts and supplies

Stallergenes Greer manufactures a broad portfolio of allergen extracts and diagnostic tests.

Veterinary use

From allergen testing to making precision treatment medicines, Stallergenes Greer is committed to providing veterinary specialists with products that can help treat animal allergies.

In the U.S., Stallergenes Greer offers a comprehensive range of allergen extracts and supplies for veterinary dermatologists to support the needs of their clients and pet patients.

Veterinary dermatologists are veterinarians that have specialised training in the management of allergic disease. They may use products from companies like Stallergenes Greer to compound named patient allergy products for dogs, cats, horses, and more.

Stallergenes Greer produces extracts of different strengths and formulations specifically for veterinary specialists.

Our portfolio

Not all our products and extracts are available in all geographic territories.

1/ SUBLINGUAL PRODUCTS

STALORAL®

The allergens and concentrations available vary by market.

Allergens:

MITES
D.pteronyssinus
D. Farinae
D.pte / D.far 50/50
Blomia / D.pte / D.far

GRASSES
5 Grasses
Cocksfoot
Timothy
Bermuda Grass

TREES
Birch
Ash
Alder
Hazel
Olive
2 Trees Mix (Ash / Olive)
3 Trees Mix
(Alder / Birch / Hazel)
Cupressaceae
Birch / Timothy Mix

DANDER
Cat epithelia
Cat IR300

WEEDS
Ragweed
Wall pellitory
Mugwort

MOULDS
Alternaria

POLLEN MIX
Birch / Ash
5 Grasses / Olive
5 Grasses / Birch
5 Grasses / Rye
5 Grasses / Juniperus
5 Grasses / Ash
5 Grasses / Berm. Grass
5 Grasses / 3 trees
5 Grasses / Ragweed
Birch / Timothy
Olive / Ash
Cupressaceae / Olive
Birch / Olive
Ragweed / Mugwort
5 Grasses / Mugwort
5 Grasses / Cynodon

ORALAIR®/ AITGRYS®

A five grass pollen mixture composed of Cocksfoot *(Dactylis glomerata L.)*, Sweet vernal grass *(Anthoxanthum odoratum L.)*, Rye grass *(Lolium perenne L.)*, Meadow grass *(Poa pratensis L.)* and Timothy *(Phleum pratense L.)*.

ACTAIR®/ ORYLMYTE®/ AITMYTE®

A house dust mite *(Dermatophagoides pteronyssinus and Dermatophagoides farinae)* mixture.

2/ SUBCUTANEOUS PRODUCTS

ALUSTAL®

ALBEY VENOM®*

3/ VETERINARY PRODUCTS

VET EXTRACTS

Allergens:

TREES & SHRUBS
Acacia
Alder, Hazel
Alder, Red
Alder, White
Ash, Arizona
Ash, Oregon
Ash, Red/Green
Ash, White
Aspen
Bayberry/Was Myrtle
Beech, American
Birch, Black/Sweet
Birch, River
Birch, Spring
Birch, White
Box Elder
Cedar, Mountain
Cedar, Red
Cedar, Salt/Tamarisk
Cottonwood, Black
Cottonwood, Eastern
Cottonwood, Fremont
Cottonwood, Western
Cypress, Arizona
Cypress, Bald
Elm, American
Elm, Cedar/Fall Blooming
Elm, Siberian
Eucalyptus
Hackberry
Hazelnut, American
Hickory, Shagbark
Hickory, Shellbark
Hickory, White
Juniper, Oneseed
Juniper, Pinchot
Juniper, Rocky Mountain
Juniper, Utah
Juniper, Western
Locust Blossom, Black
Mango Blossom
Maple, Red
Maple, Silver/Soft
Maple, Sugar/Hard
Melaleuca
Mesquite
Mulberry, Paper
Mulberry, Red
Mulberry, White
Oak, Arizona/Gambel
Oak, Black
Oak, Bur
Oak, California Black
Oak, California Live
Oak, California White
Oak, Post
Oak, Red
Oak, Virginia Live
Oak, Water
Oak, Western White
Oak, White
Olive
Olive, Russian
Orange Pollen
Palm, Queen
Pecan
Pepper Tree
Pine, Australian (Beefwood)
Pine, Loblolly
Pine, Longleaf
Pine, Ponderosa
Pine, Virginia/Scrub
Pine, Eastern White
Pine, Western White
Pine, Yellow
Poplar, Lombardy
Poplar, White
Privet, Common
Sweet Gum
Sycamore, American/ Eastern
Sycamore, Western
Walnut, Black
Walnut, California Black
Walnut, English
Willow, Arroyo
Willow, Black
2 Maple Mix
3 Maple Mix
11 Tree Mix
Ash Mix
Birch Mix
Eastern 6 Tree Mix
Eastern 7 Tree Mix
Eastern 8 Tree Mix
Eastern 10 Tree Mix
Eastern Oak Mix
Elm Mix
Hickory Mix
Hickory-Pecan Mix
Maple-Box Elder Mix
Pine Mix
Western 10 Tree Mix
Western Oak Mix
Western Walnut Mix
Daisy Ox-Eye
Dandelion
Sunflower
Alfalfa
Mustard
Red Clover
Sugar Beet

WEEDS
Allscale
Baccharis
Burrobrush
Careless Weed, Amaranth/ Green
Cocklebur
Dock, Yellow/Curly
Dog Fennel
Firebush/Kochia
Goldenrod
Hemp, Water
Iodine Bush
Lambs Quarter
Lenscale/Quailbrush
Marsh Elder, Burweed/Giant Poverty
Marsh Elder, True/Rough
Mugwort, Common
Mugwort, Darkleaved/
Sagebrush, Prairie
Nettle
Palmer's Amaranth
Pigweed, Rough/Redroot
Plantain, English
Rabbit Bush
Ragweed, Desert
Ragweed, False
Ragweed, Giant
Ragweed, Short
Ragweed, Slender
Ragweed, Southern
Ragweed, Western
Russian Thistle
Sagebrush, Common
Saltbush, Annual
Sorrel, Sheep/Red
Wingscale
3 Weed Mix
Dock-Sorrel Mix
Pigweed Mix
Plantain-Sorrel Mix
Ragweed Mix
Sage Mix
Scale/Atriplex Mix
Western Ragweed Mix

GRASSES
Bahia Grass
Bermuda
Brome Grass, Smooth
Canarygrass
Corn, Cultivated
Couch/Quack Grass
Johnson Grass
Kentucky Blue/June
Meadow Fescue
Oats, Common/Cultivated
Orchard
Redtop

RYE, CULTIVATED
Ryegrass, Giant Wild
Ryegrass, Italian
Ryegrass, Perennial
Sweet Vernal
Timothy
Velvetgrass
Wheat Cultivated
Wheatgrass, Western
7 Grass Mix
9 Southern Grass Mix
Bermuda-Johnson Grass Mix
K-O-R-T Grass Mix

FUNGI & SMUTS
Acremonium strictum
Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans
Chaetomium globosum
Cladosporium herbarum
Cladosporium sphaerospermum
Drechslera spicifera
Epicossum nigrum
Epidermophyton floccosum
Fusarium moniliforme
Fusarium solani
Geotrichum candidum
Gliocladium viride
Helminthosporium solani
Malassezia pachydermatis
Mucor circinelloides f. circinelloides
Mucor circinelloides f. lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum (notatum)
Penicillium digitatum
Phoma betae
Rhizopus oryzae
Rhizopus stolonifer
Rhodotorula mucilaginosa var. mucilaginosa
Saccharomyces cerevisiae
Stemphylium solani
Trichoderma harzianum
Trichophyton mentagrophytes
Trichophyton rubrum
Trichothecium roseum
Aspergillus Mix
Dematiaceae Mix
Fusarium Mix
Mold Mix #1
Mold Mix #2
Mold Mix #3
Monilia Mix
Mucor mix
Penicillium Mix
Phycomycetes Mix
Rhizopus Mix
Corn Smut
Grain Smut mix
Grass Smut Mix

EPITHELIA
Cat Epithelia
Cattle Epithelia
Dog Epithelia
Gerbil Epithelia
Goat Epithelia
Guinea Pig Epithelia
Hamster Epithelia
Hog Epithelia
Horse Epithelia
Human Dander
Mouse Epithelia
Rabbit Epithelia
Rat Epithelia
Sheep Epithelia

FEATHERS & MISCELLANEOUS INHALANTS
Canary Feathers
Chicken Feathers
Duck Feathers
Parakeet Feathers
Feather Mix
Cotton Linters
Cottonseed
Flaxseed
Kapok Seed
Orris Root
Pyrethrum
Silk
Tobacco Leaf

INSECTS
Ant, Black/Carpenter
Ant, Fire – Solenopsis richteri
Ant, Fire – Solenopsis invicta
Cockroach, American
Cockroach, German
Culicoids
Deer Fly
Flea
Horse Fly
House Fly
Mosquito
Moth
2 Cockroach Mix
4 Insect Mix

DUST & DUST MITES
Dust, House
Grain Mill Dust Mix
Acarus siro
Blomia tropicalis
Dermatophagoides farinae
Dermatophagoides pteronyssinus
Lepidoglyphus destructor
Tyrophagus putrescentiae
Equal Parts Mixture

VET OTHER SUPPLIES

STERILE DILUENTS

NONSTERILE EMPTY VIALS

STERILE EMPTY VIALS

PLASTIC COLORED CAPS

VIAL RACKS

AMBER VIALS AND METERED PUMPS

SYRINGES AND SYRINGE TRAYS

ANCILLARY PRODUCTS

4/ STANDARDISED HUMAN EXTRACTS

STANDARDISED CAT HAIR

STANDARDISED DERMATOPHAGOIDES FARINA MITE

STANDARDISED DERMATOPHAGOIDES PTERONYSSINUS MITE

STANDARDISED MITE MIX

STANDARDISED GRASS & POLLENS
Bermuda Grass
Kentucky Blue/June
Meadow Fescue
Orchard
Redtop
Ryegrass, Perennial
Sweet Vernal
Timothy
7 Grass Mix
K-O-R-T Grass Mix
K-O-R-T and Sweet Vernal Mix
K-O-T Grass Mix
Timothy/Orchard Grass Mix
T-O-S Grass Mix
Ragweed, Short
National Weed Mix
Ragweed Mix

POLLENS -TREES & SHRUBS
Acacia
Alder, Hazel
Alder, Red
Alder, White
Ash, Arizona (Velvet)
Ash, Green
Ash, Oregon
Ash, White
Aspen
Beech, American
Birch, Black/Sweet
Birch, River
Birch, Spring
Birch, White
Box Elder
Cedar, Mountain
Cedar, Red
Cedar, Salt (Tamarisk)
Cottonwood, Arizona (Fremont)
Cottonwood, Black
Cottonwood, Eastern
Cottonwood, Western
Cypress, Arizona
Cypress, Bald
Elm, American
Elm, Cedar
Elm, Siberian
Eucalyptus, Bluegum
Hackberry
Hazelnut, American
Hickory, Shagbark
Hickory, Shellbark
Hickory, White
Juniper, Oneseed
Juniper, Pinchot
Juniper, Rocky Mountain
Juniper, Utah
Juniper, Western
Locust Blossom, Black
Mango Blossom
Maple, Red
Maple, Silver/Soft
Maple, Sugar/Hard
Melaleuca
Mesquite, Velvet
Mulberry, Paper
Mulberry, Red
Mulberry, White
Oak, Arizona (Gambel)
Oak, Black
Oak, Bur
Oak, California Black
Oak, California Live
Oak, California White
Oak, Post
Oak, Red
Oak, Virginia Live
Oak, Water
Oak, Western White
Oak, White
Olive
Olive, Russian
Orange Pollen
Palm, Queen
Pecan
Pine, Australian (Beefwood)
Pine, Loblolly
Pine, Longleaf
Pine, Ponderosa
Pine, Virginia Scrub
Pine, Eastern White
Pine, Western White
Pine, Yellow
Poplar, Lombardy's
Poplar, White
Privet
Sweetgum
Sycamore, American
Sycamore, California (Western)
Walnut, Black
Walnut, California Black
Walnut, English
Wax Myrtle
Willow, Arroyo
Willow, Black
2 Maple Mix
3 Maple Mix
11 Tree Mix
Birch Mix
Central/Eastern 4 Tree Mix
Eastern 6 Tree Mix
Eastern 7 Tree Mix
Eastern 8 Tree Mix
Eastern 9 Tree Mix
Eastern 10 Tree Mix
Eastern Oak Mix
Elm Mix
Hickory Mix
Hickory-Pecan Mix
Juniper Mix
Maple-Box Elder Mix
Peppertree Mix
Pine Mix
Western 3 Tree Mix
Western 10 Tree Mix
Western Oak Mix
Western Walnut Mix

POLLENS – FLOWERS & PLANTS
Daisy
Dandelion
Sunflower
Alfalfa
Rape (Mustard)
Red Clover
Sugar Beet

POLLENS - WEEDS
Allscale
Amaranth, Green
Burningbush (Kochia)
Burrobrush
Cocklebur
Dock, Yellow (Curly)
Dogfennel
Goldenrod
Iodinebush
Lamb's Quarters
Lenscale (Quailbrush)
Marshelder, Burweed (Giant Poverty)
Marshelder, True (Rough)
Mugwort, Common
Nettle
Palmer's Amaranth
Pigweed, Rough Redroot
Pigweed, Spiny
Plantain, English
Rabbit Bush
Ragweed, Desert
Ragweed, False
Ragweed, Giant (Tall)
Ragweed, Lanceleaf
Ragweed, Slender
Ragweed, Western
Russian Thistle
Sagebrush, Common
Saltbush, Annual
Sorrel, Sheep (Red)
Waterhemp, Tall
Wingscale
3 Weed Mix
Baccharis Mix
Central/Western Weed Mix
Common Weed Mix
Dock-Sorrel Mix
Pigweed Mix
Plantain-Sorrel Mix
Sage Mix
Scale/Atriplex Mix
Western Ragweed Mix

POLLENS - GRASSES
Brome, Smooth
Canary Grass, Reed
Corn, Cultivated
Johnson Grass
Oats, Cultivated
Quack (Couch) Grass
Rye, Cultivated
Ryegrass, Giant Wild
Ryegrass, Italian
Velvetgrass
Wheat, Cultivated
Wheatgrass, Western

MOULDS
Alternaria alternata
Aspergillus amstelodami
Aspergillus flavus
Aspergillus fumigatus
Aspergillus nidulans
Aspergillus niger
Aureobasidium pullulans
Bipolaris sorokiniana
Botrytis cinerea
Candida albicans*
Chaetomium globosum
Cladosporium herbarum
Cladosporium sphaerospermum
Curvularia spicifera
Epicossum nigrum
Epidermophyton floccosum
Fusarium solani
Geotrichum candidum
Gibberella fujikuroi
Gliocladium viride
Helminthsporium solani
Hypomyces perniciosus
Microsporum canis
Mucor circinelloides f. circinelloides
Mucor circinelloides f. lusitanicus
Mucor plumbeus
Neurospora intermedia
Paecilomyces variotii
Penicillium chrysogenum var. chrysogenum
Penicillium digitatum
Phoma betae
Rhizopus arrhizus
Rhizopus stolonifer
Rhodotorula mucilaginosa
Saccharomyces cerevisiae
Sarocladium strictum
Stemphylium solani
Trichoderma harzianum
Trichophyton mentagrophytes
Trichophyton rubrum
Trichothecium roseum
AHH Mix
Alternaria/Hormodendrum Mix
Aspergillus Mix
Dematiaceae Mix
Fusarium Mix
Mold Mix #1
Mold Mix #2
Mold Mix #3
Monilia Mix
Mucor Mix
New Stock Fungi Mix
Penicillium Mix
Phycomycetes Mix
Rhizopus Mix
Bermuda Grass Smut
Corn Smut
Loose Smut of Barley
Loose Smut of Wheat
Oat Smut
Grain Smut Mix
Grass Smut Mix

EPITHELIA
Cattle Epithelia
Dog Epithelia
Gerbil Epithelia
Goat Epithelia
Guinea Pig Epithelia
Hamster Epithelia
Hog Epithelia
Horse Epithelia
Mouse Epithelia
Rabbit Epithelia
Rat Epithelia
Canary Feathers
Chicken Feathers
Duck Feathers
Parakeet Feathers
Feather Mix
Cotton Linters
Cottonseed
Flax
Gum Arabic
Gum Karaya
Gum Tragacanth
Kapok
Leaf Tobacco, Cultivated
Orris Root
Pyrethrum
Silk Worm Cocoon
Ant, Black Carpenter
Fire Ant – Solenopsis richteri
Fire Ant – Solenopsis invicta
Cockroach, American*
Cockroach, German*
Deer Fly
Flea (Aqueous Only)
House Fly
Mosquito
2 Cockroach Mix

FOODS
Apple
Apricot
Banana
Barley, Whole Grain
Bean, Lima
Bean, Navy
Bean, String Green
Blueberry, Velvetleaf
Broccoli
Buckwheat
Cabbage
Cantaloupe
Carrot
Cauliflower
Celery
Cherry, Sweet
Cacao Bean
Cinnamon
Coffee
Corn
Cranberry
Cucumber
Garlic
Ginger
Grape, White Seedless
Grapefruit
Hops
Lemon
Lettuce
Malt
Mushroom
Mustard Seed
Nutmeg
Oat
Olive, Green
Onion
Orange
Pea, Green or English
Peach
Pear
Pepper, Black
Pepper, Green
Pineapple
Potato, Sweet
Potato, White
Raspberry, Red
Rice
Rye
Sesame Seed
Soybean
Spinach
Squash, Yellow Summer
Strawberry
Tomato
Vanilla
Watermelon
Wheat, Whole
Beef
Lamb
Pork
Chicken Meat
Egg White, Chicken
Egg Whole, Chicken
Egg Yolk, Chicken
Turkey Meat
Milk, Cow
Bass, Black
Catfish, Channel
Clam, Northern Quahog
Cod, Atlantic
Crab, Blue
Flounder, Southern
Lobster, American
Mackerel, King/Atlantic
Oyster, Atlantic/Eastern
Perch, Ocean
Salmon, Atlantic
Scallops, Sea
Shrimp, Brown
Trout, Rainbow
Tuna, Yellowfin
Fish, Mix
Shellfish Mix
Almond
Brazil Nut
Cashew Nut
Coconut
Hazelnut (Filbert)
Peanut
Pecan
Walnut, Black
Walnut, English

5/ PRICK TESTS

40-WELL SKIN OMNI™ EVALUATION PACKAGE

40-WELL GREER® PICK® EVALUATION PACKAGE

60-WELL SKIN OMNI™ EVALUATION PACKAGE

60-WELL GREER® PICK® EVALUATION PACKAGE

ALYOSTAL PRICK ®

Positive control (Histamin)
Negative control
D. Pteronyssinus
D. Farinae
5 Grasses
Birch
Ragweed
Hazel
Olive
Cupressacee
Cat dander
Mugwort
Alder
Ash
Wall pellitory
Blomia
Cynodon
Rye grass
Alternia
Artemisia
Bermuda grass
Latex

GREER® PICK®

GREER® PICK® TRAY™

GREER® PICK® TRAY™

LID PRICK LANCET®

STALLERPOINT®

GREER® PICK® WELL™

SKINTESTOR OMNI™

SKINTESTOR OMNI™ SYSTEM

SKINTESTOR OMNI™ TRAYS

THE GREER® PICK® SYSTEM

6/ OTHER SUPPLIES

DOM' HOUS®

GREER® STERILE DILUENTS™

GREER® STERILE EMPTY VIALS™

GREER® VERSA VIAL RACK

ANCILLARY PRODUCTS

GREER PHARMACY – NAMED PATIENT PRODUCTS

JIFFY MAILING BAGS

MAILING CONTAINERS

NONSTERILE EMPTY VIALS

PLASTIC COLOURED CAPS

SAFETY SYRINGES STERILE DILUENTS

SHARPS COLLECTORS

SKIN REACTION GUIDES

STERILE EMPTY VIALS

STOCK AND CUSTOM-PRINTED LABELS

STYROFOAM CONTAINERS

SYRINGES AND SYRINGE TRAYS

VIAL RACKS

** Progressive resumption of production*

STALLERGENES GREER INTERNATIONAL AG
Zugerstrasse 76b
6340 Baar, Switzerland

2022 In Review is available on the Group's website **www.stallergenesgreer.com**.

CONCEPTION AND EDITORIAL FOLK FORMAN, 68 rue de la Chaussée d'Antin, 75009 Paris, FRANCE **www.folkforman.com**

CREATION AND PRODUCTION MPG VISUAL DESIGN, PO Box 1002, Manzanita, OR 97130, USA **www.mpgvisualdesign.com**

PHOTO CREDITS All rights reserved - Pierre-Olivier Callede - Gérard Uféras (p 2, 4, 8, 10, 13, 23) - Rusty Williams (p 27) - Shutterstock.com (p 10, 19, 26) - Getty Images (p 14, 16, 18, 54-56) - Adobe Stock (p 14, 29) - Unsplash: Kristen Morith (p 17) - Vecteezy (p 17)

Printed in France by Noël Imprimeur Paris - Imprim'Vert® certified printer - on paper from sustainable forests in an ISO 14001 and EMAS certified facility.

Completed March 28, 2023

Thank you to all patients, physicians and Stallergenes Greer employees who appear in this publication. All product names listed in this document are registered trademarks of the Stallergenes Greer group - Produced by Stallergenes Greer, Global Communications and Corporate Responsibility.

Follow us on

www.linkedin.com/company/stallergenesgreer

twitter.com/StallergenesCom

STALLERGENES GREER INTERNATIONAL AG
Zugerstrasse 76b
6340 Baar, Switzerland

2023_033EN01 April 2023